Mein Warenkorb

H-2Kb | B2M

Produktanfrage

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
LM-305LM-305Phase 2 ClinicalLaNova Medicines LtdMultiple Myeloma
Details
SAR-446523SAR-446523Phase 2 ClinicalSanofi-Aventis GmbhBone Marrow Neoplasms; Multiple Myeloma
Details
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
IBI-3003IBI3003; IBI-3003Phase 2 ClinicalInnovent Biologics(Suzhou) Co LtdMultiple Myeloma
Details
BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital)Phase 2 ClinicalGuangzhou Bio-Gene Technology Co Ltd, Wuhan Union HospitalMultiple Myeloma
Details
MBS-314MBS-314Phase 2 ClinicalBeijing Mabworks Biotech Co LtdMultiple Myeloma
Details
CT-071CT071; CT-071Phase 2 ClinicalCARsgen Therapeutics Holdings LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
Anti-GPRC5D CAR-T Cells Therapy(920th Hospital)Phase 2 ClinicalThe 920th Hospital Of Joint Logistics Support Force Of PLAMultiple Myeloma
Details
Ori-CAR-017Ori-CAR-017; OriCAR-017; GPRC5D-CAR-TPhase 2 ClinicalOriCell Therapeutics Co LtdHematologic Diseases; Hemorrhagic Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders
Details
LBL-034LBL-034Phase 2 ClinicalNeoplasms; Multiple Myeloma
Details
CC-95266CC-95266; BMS986393; BMS-986393Phase 2 ClinicalJuno Therapeutics IncMultiple Myeloma
Details
RD-140RD140Phase 1 ClinicalNanjing Iaso Biotherapeutics Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)BMS-986453Phase 1 ClinicalJuno Therapeutics IncMultiple Myeloma
Details
SIM-0500SIM0500; SIM-0500Phase 1 ClinicalSimcere Pharmaceutical Group LtdBone Marrow Neoplasms; Multiple Myeloma
Details
QLS-32015QLS-32015; QLS32015Phase 1 ClinicalQilu Pharmaceutical Co LtdMultiple Myeloma
Details
OriC-321OriC-321; Ori-C-321Phase 1 ClinicalZhejiang University, OriCell Therapeutics Co LtdMultiple Myeloma
Details
CAR-GPRC5DCAR-GPRC5DPhase 1 ClinicalNanjing Iaso Biotherapeutics Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
ForimtamigRG-6234Phase 1 ClinicalF. Hoffmann-La Roche LtdMultiple Myeloma
Details
MCARH-109Phase 1 ClinicalMemorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics IncMultiple Myeloma
Details
RO-7425781RO-7425781Phase 1 ClinicalF. Hoffmann-La Roche LtdMultiple Myeloma
Details
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province)The Second People Hospital Of Guangdong Province
Details
Anti-GPRC5D CAR-T Cells Therapy(Institute of Hematology & Blood Diseases Hospital)Institute Of Hematology & Blood Diseases Hospital
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
TalquetamabJNJ-7564; JNJ-64407564ApprovedGenmab A/S, Johnson & Johnson Innovative MedicineTALVEYUnited StatesMultiple MyelomaJanssen Biotech Inc2023-08-09Hematologic Neoplasms; Multiple Myeloma
Details
  • Produktanfrage
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns